ライフサイエンスコーパス: modified Rankin Scale

1 deficits and the patient was rated 0 in mRS (modified Rankin Scale).

2 by functional outcome at hospital discharge (modified Rankin scale).

3 rdiovascular events, and functional outcome (modified Rankin scale).

4 Functional ability was rated with the modified Rankin scale.

5 good and poor outcomes as determined by the modified Rankin Scale.

6 s, patient and physician reported, including modified Rankin scale.

7 ral Performance Category (CPC) scale and the modified Rankin scale.

8 nd outcome at 3 months was assessed with the modified Rankin Scale.

9 elated with scores on Glasgow Coma Scale and modified Rankin scale.

10 severity of stroke was graded according to a modified Rankin scale.

11 at least one postbaseline measurement of the modified Rankin Scale.

12 g a functionally independent outcome (90-day modified Rankin Scale 0-2) by 8.3% (P=0.006).

13 A "good" outcome was defined as modified Rankin Scale 0-3, Barthel Index 70-100, and Gla

14 mortality, (2) favorable functional outcome (modified Rankin Scale = 0-3), and (3) stroke incidence.

15 Patients who were independent (modified Rankin Scale, 0-3) at discharge or 14 days had

16 Poor outcome was defined as modified Rankin Scale 4-6 at 3 months after SAH.

17 % vs. 3%, p=0.031), death/severe disability (modified Rankin Scale 4-6; 53% vs. 15%, p=0.003) and wor

18 ssociated with reduced risk of poor outcome (modified Rankin Scale, 4-6) at 14 days/discharge and 3 m

19 ctional independence (score of 0 to 2 on the modified Rankin scale, 71% vs. 40%; P=0.01).

20 severe disability or death according to the modified Rankin scale 90 days after the stroke.

21 en readmission and functional outcomes using modified Rankin Scale (a validated functional outcome me

22 severity of disability over the range of the modified Rankin scale (adjusted odds ratio for improveme

23 mortality (7.7% vs 7.3%; p=0.93) and median modified Rankin Scale after 6 months (3 vs 3; p=0.94).

24 The modified Rankin Scale and Barthel Index were more sensit

25 We simultaneously assessed the modified Rankin Scale and health-related quality of life

26 The outcome was assessed using the modified Rankin Scale and school performance in children

27 Readmitted patients had similar modified Rankin Scale and severity of neurologic deficit

28 Relationship between outcome (modified Rankin Scale) and interval times was modeled by

29 Handicap was studied with the modified Rankin scale, and cerebral abnormalities with t

30 functional outcome measures (Barthel index, modified Rankin scale, and Glasgow Outcome Scale) at day

31 trumental activities of daily living (IADL), modified Rankin Scale, and NIH Stroke Score.Compared to

32 bility as measured by the Barthel index, the modified Rankin Scale, and the Glasgow Outcome Scale.

33 ed the overall distribution of scores on the modified Rankin scale, as compared with placebo (P=0.038

34 Outcomes were measured with the modified Rankin Scale at 14 days or discharge, and at 3

35 The primary outcome was the score on the modified Rankin scale at 2 years; this scale measures fu

36 with treatment allocation concealed, by the modified Rankin scale at 6 months (independence [scores

37 tcomes were seen for the Hp2-2 patients with modified Rankin scale at 6 wk (P = 0.076) and at 1 y (P

38 e was functional outcome, as measured by the modified Rankin Scale at 90 days and reported as adjuste

39 The mean score on the utility-weighted modified Rankin scale at 90 days was 5.5 in the thrombec

40 utcomes included the functional score on the modified Rankin scale at 90 days.

41 bility among the 2 groups as measured by the modified Rankin scale at 90 days.

42 -PA complication, in-hospital mortality, and modified Rankin Scale at discharge across 3 groups.

43 gest correlation with a score of subacute on modified Rankin scale at discharge.

44 of 90-day disability outcomes on the global modified Rankin scale between patients in the magnesium

45 Thirteen patients (50%) improved on the modified Rankin Scale by 1-3 points and four (15%) worse

46 which combines dichotomised results from the modified Rankin scale, change in NIHSS score from baseli

47 had shifted down by at least 1 point on the modified Rankin Scale compared to day 7.

48 important determinant, regardless of day or modified Rankin Scale cut point (mean odds ratio 12.51,

49 Among all patients, mean scores on the modified Rankin scale did not differ between embolectomy

50 The distribution of outcomes on the modified Rankin scale favored endovascular treatment ove

51 14 (28%) who were not treated; reductions in modified Rankin Scale for children scores were more comm

52 days, as measured according to scores on the modified Rankin scale for disability (range, 0 to 5, wit

53 , and 12 months postcardiac arrest using the modified Rankin Scale, Glasgow Outcome Scale, and Barthe

54 res were discharge Glasgow Coma Scale (GCS), modified Rankin Scale, Glasgow Outcome Scale, and hospit

55 mortality and unfavorable outcomes (death or modified Rankin Scale, Glasgow Outcome Scale, or World F

56 Morbidity and mortality (modified Rankin Scale>2) at 1 year occurred in 2/48 (4.2

57 r hyperintensities were associated with poor modified Rankin Scale improvement: adjusted odds ratios

58 hich was defined as a score of 3 to 6 on the modified Rankin scale (in which a score of 0 indicates n

59 The modified Rankin Scale is a sensitive outcome scale in th

60 on the rate of excellent outcome at 90 days (modified Rankin Scale </= 2) in each tertile of admissio

61 ed patients aged 18 to 85 years, prehospital modified Rankin Scale </=3, ICH volume < 60ml, Glasgow C

62 an odds ratio 12.51, range [6.01, 22.56] for modified Rankin Scale </=3; mean odds ratio 19.26, range

63 mean odds ratio 62.61, range [2.24, 177] for modified Rankin Scale </=3; mean odds ratio 34.13, range

64 2.35, 95% confidence interval 0.64-5.74 for modified Rankin Scale </=3; odds ratio 2.1, 95% confiden

65 an odds ratio 34.13, range [4.95, 89.93] for modified Rankin Scale </=4).

66 an odds ratio 19.26, range [5.38, 42.26] for modified Rankin Scale </=4).

67 good outcome was determined at two levels by modified Rankin Scale, </=3 as independence and </=4 as

68 ty outcome) and 3-month death or dependency (modified Rankin Scale (mRs) >/=3;efficacy outcome), in p

69 atment and control groups as measured by the modified Rankin Scale (mRS) (with scores ranging from 0

70 econdary outcomes were functional outcome by modified Rankin Scale (mRS) after 3 months (0-6 [symptom

71 nd at days 5 (or discharge), 30, and 90; and modified Rankin Scale (mRS) and Barthel Index (BI) at da

72 assessed the growth of the infarct, and the modified Rankin Scale (mRS) assessed functional outcome

73 ift towards death or dependence rated on the modified Rankin Scale (mRS) at 3 months, and analysed by

74 outcome assessed by ordinal analysis of the modified Rankin scale (mRS) at 90 days in the GA and non

75 primary outcome of reduced disability on the modified Rankin Scale (mRS) at 90 days.

76 Clinical outcome was determined by the modified Rankin Scale (mRS) at discharge and in-hospital

77 stigated whether automatic assessment of the modified Rankin Scale (mRS) based on a mobile phone ques

78 Functional outcome was defined by modified Rankin scale (mRS) dichotomized into good (mRS,

79 ieving good functional outcome, defined as a modified Rankin scale (mRS) of 0 to 2 (RR: 1.45; 95% con

80 Day 90 modified Rankin Scale (mRS) outcomes for OTR time interv

81 were no stroke or TIA, TIA, and stroke with modified Rankin Scale (mRS) score 0 to 1, mRS 2 to 3, an

82 lity assessed by overall distribution of the modified Rankin Scale (mRS) score at 90 days, change in

83 ility, activities of daily living (ADLs) and Modified Rankin Scale (MRS) score at admission and disch

84 Main outcome was the modified Rankin Scale (mRS) score for functional outcome

85 The primary outcome was the distribution of modified Rankin Scale (mRS) score obtained by questionna

86 patients achieving independence defined by a modified Rankin Scale (mRS) score of 0-2 at day 90.

87 troke Scale (NIHSS) over 24 hours and 90-day modified Rankin Scale (mRS) score of 0-2.

88 as the proportion of patients who achieved a modified Rankin Scale (mRS) score of 0-4 at 90 days with

89 to development of neurological symptoms, and modified Rankin Scale (mRS) score.

90 y clinical end point was 90-day dichotomized modified Rankin Scale (mRS) score.

91 The primary outcome was 90 day modified Rankin Scale (mRS) score.

92 ween treatment groups with shift analysis of modified Rankin Scale (mRS) score.

93 e; clinical improvement in NIHSS; and 90-day modified Rankin Scale (mRS) score.

94 Ordinal improvement across modified Rankin scale (mRS) scores at 90 days, functiona

95 Modified Rankin Scale (mRS) scores at discharge and othe

96 te end points of death and major disability (modified Rankin scale (mRS) scores of 3-6, 6 and 3-5, re

97 tics, stroke severity and type, end-of-trial modified Rankin Scale (mRS), Barthel Index, haematologic

98 follow-up was disability, measured using the modified Rankin Scale (mRS), ranging from 0 (no symptoms

99 ity of life outcomes were measured using the modified Rankin scale (mRS), Telephone Interview for Cog

100 stitutes of Health stroke scale (NIHSS), the modified Rankin scale (mRS), the Barthel index (BI), the

101 t months 4, 8, 12, 18, and 24, by use of the modified Rankin scale (mRS).

102 Outcome was evaluated at 12 months using the modified Rankin Scale (mRS).

103 al Institutes of Health Stroke Scale and the modified Rankin Scale (mRS).

104 uding case-fatality rate, favorable outcome (modified Rankin Scale [ mRS modified Rankin Scale ] scor

105 ses of periprocedural death or major stroke (modified Rankin Scale [mRS] > 3) (95% confidence interva

106 e primary outcome was death or poor outcome (modified Rankin scale [MRS] grade 3-5), 6 months after e

107 o hospital discharge with favorable outcome (modified Rankin scale [mRS] score of 0-3).

108 outcome was dependence or death at 3 months (modified Rankin Scale [mRS] score of 3-6).

109 troke Scale score, time from onset, baseline modified Rankin Scale [mRS] score, life expectancy).

110 functional outcomes (Barthel index [BI] and modified Rankin scale [mRS]), the incidence of intracere

111 sed the odds of being alive and independent (modified Rankin Scale, mRS 0-2) at final follow-up (1611

112 ples from 45 patients (25 with good outcome [modified Rankin Scale, mRS 0-2], ten with poor outcome [

113 Favorable outcome (defined as modified Rankin scale of <or=2) and death at 1-month was

114 proportion (6.8% [4.0% to 9.5%]) achieving a modified Rankin Scale of 0 or 1 (excellent outcome) exce

115 Favorable outcome was defined as a modified Rankin Scale of 0 to 3 at first follow-up.

116 ity of survival to hospital discharge with a modified Rankin scale of 0 to 3 declines rapidly with ea

117 ospital discharge was 11%, but only 6% had a modified Rankin scale of 0 to 3.

118 death or dependence at 1 year (defined by a modified Rankin scale of 3-6).

119 se were considered neurologically recovered (modified Rankin scale of zero), while 36 patients were n

120 schaemic or haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days, as assesse

121 available at all timepoints improved to good modified Rankin Scale outcome and none worsened to poor

122 days over the entire range of scores on the modified Rankin scale (P<0.001).

123 es (as indicated by a score of 0 to 1 on the modified Rankin scale) (P=0.20).

124 ome was assessed at 3 and 12 months with the modified Rankin Scale; quality of life (QOL), with the S

125 The primary outcome was the score on the modified Rankin scale (range, 0 [no symptoms] to 6 [deat

126 ity at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores

127 al disability at 90 days, as measured on the modified Rankin scale (ranging from 0 [no symptoms] to 6

128 We assessed outcomes using the 90-day modified Rankin scale, ranging from 0 (no symptoms) to 6

129 me was death or major disability at 90 days (modified Rankin Scale score >/=3) and the secondary outc

130 a combination of death and major disability (modified Rankin Scale score >/=3) at 3 months.

131 or improved outcome (relative risk of 90-day modified Rankin Scale score >/=4, 1.24; 95% CI, 0.53-2.9

132 e < or =2 points] to disability at 6 months [modified Rankin scale score >2 points]) or death, compar

133 progression from no disability before event [modified Rankin scale score < or =2 points] to disabilit

134 = .01), and had better outcome (defined by a modified Rankin Scale score </= 2 at last visit; 84% vs

135 ollow-up of 7.4 years, 82% of patients had a modified Rankin Scale score </= 2.

136 outcome was 3-month functional independence (modified Rankin scale score </=2).

137 38%) achieved moderate disability or better (modified Rankin Scale score </=3) by 1 year after stroke

138 o 2.1, 95% confidence interval 0.81-4.24 for modified Rankin Scale score </=4).

139 The primary outcome was a favourable modified Rankin Scale score (0-2) at day 90 in all treat

140 Modified Rankin Scale score (0-2) at day 90 occurred in

141 The primary outcome was reported using the modified Rankin Scale score (disability range, 0 [no sym

142 me was good functional outcome, defined as a modified Rankin Scale score (mRS) of 3 or less at 180 da

143 Secondary outcomes included the modified Rankin scale score (on a scale from 0 to 6, wit

144 mortality, discharge ambulatory status, and modified Rankin Scale score (range, 0 [no symptoms] to 6

145 m PSC door to CSC groin puncture, and 90-day modified Rankin Scale score (range, 0-6; scores of 0-2 i

146 Measures: The primary outcome was the 90-day modified Rankin Scale score (range, 0-6; scores of 0-2 i

147 h functional outcome significantly improved (modified Rankin Scale score 0-1 in 375 [40%] of 944 pati

148 ent outcomes when treated with tenecteplase (modified Rankin scale score 0-1: odds ratio, 1.77; 95% c

149 0.001) and better late independent recovery (modified Rankin scale score 0-1: odds ratio, 2.33; 95% c

150 Favorable clinical outcome was defined as modified Rankin scale score 0-2 at 3 months after stroke

151 ith neurosurgical clipping were independent (modified Rankin scale score 0-2; OR 1.25; 95% CI 0.92-1.

152 f Health Stroke Scale [NIHSS] score >/=6 and modified Rankin Scale score 2-4) 6-60 months after ischa

153 002]) and to advanced functional disability (modified Rankin Scale score 3 to 6 vs. 0 to 2: 135.1 pmo

154 We assessed functional outcome (modified Rankin scale score 3-6) and mortality at 90 day

155 2.45x10(-5)) and poorer functional outcomes (modified Rankin scale score 3-6; 1.52, 1.25-1.85; p=1.74

156 Independent predictors of poor modified Rankin Scale score at 30 days were percent of i

157 The primary efficacy end point was the Modified Rankin Scale score at 90 days after stroke onse

158 Primary outcome was the modified Rankin Scale score at 90 days.

159 The primary outcome was the modified Rankin scale score at 90 days; this categorical

160 After ICH, the modified Rankin scale score at discharge was >/=4 in 55.

161 sociated with any significant changes in the modified Rankin scale score distribution (MAC: OR, 1.52;

162 ed with the placebo group at 90 days (median Modified Rankin Scale score for all 3 treatment groups =

163 sitivity, 30% [95% CI: 18%, 45%]) or 6-month modified Rankin scale score greater than 3 (specificity,

164 ncy at 2 weeks, with dependency defined as a modified Rankin scale score greater than 3 points.

165 ma expansion rate was associated with poorer modified Rankin Scale score in an ordinal shift analysis

166 We assessed dependency as self-reported modified Rankin scale score obtained through yearly ques

167 rest were mortality and poor 90-day outcome (modified Rankin Scale score of >/=3).

168 Frequency of good outcome (defined as a modified Rankin Scale score of </= 2) and mortality at 6

169 harge with favourable neurological function (modified Rankin scale score of </=3).

170 Scale score of >or=8 points at 30 days or a modified Rankin scale score of 0 or 1 at 30 days) in pat

171 tients who had an excellent outcome (i.e., a modified Rankin scale score of 0 or 1).

172 was favourable outcome, defined as either a modified Rankin scale score of 0 or 1, or an NIHSS score

173 Favorable outcome was defined as a modified Rankin Scale score of 0 to 1 at 3 months.

174 Stroke Scale and a favorable odds ratio of a modified Rankin scale score of 0 to 1 versus 2 to 6 comp

175 Good (moderate) outcome was defined as a modified Rankin Scale score of 0 to 2 (0-3) assessed aft

176 No patients had a modified Rankin scale score of 0 to 2 (survival with no

177 es, rates of acceptable outcome defined as a modified Rankin Scale score of 0 to 3 at hospital discha

178 to model good clinical outcome (defined as a modified Rankin Scale score of 0-2 at 3 months) as a fun

179 Good outcome was defined as a modified Rankin Scale score of 0-2 at follow-up.

180 Functional independence (modified Rankin Scale score of 0-2) and mortality at 3 m

181 essful reperfusion, functional independence (modified Rankin Scale score of 0-2) and mortality at 90

182 t 6 months after ICU admission, defined by a modified Rankin Scale score of 0-2.

183 The primary outcome measure was a modified Rankin scale score of 2 or less (indicating fun

184 baseline NIHSS score of 10 or higher, with a modified Rankin Scale score of 2 or less achieved in onl

185 nt was good functional outcome, defined as a modified Rankin scale score of 2 or less at day 90.

186 MCA-M2 occlusions, respectively, achieved a modified Rankin Scale score of 2 or less, and 6 (23.1%),

187 Poor 3-month outcome was defined as modified Rankin Scale score of 3 to 6.

188 utcome was the proportion of patients with a modified Rankin scale score of 3-6 (dependency or death)

189 ad or disabled at discharge (77% vs 65% with modified Rankin Scale score of 3-6; AOR = 1.64; 95% CI,

190 unfavorable outcome was defined as a 90-day modified Rankin Scale score of 4 or greater (range, 0-6)

191 d or were severely disabled (as defined by a modified Rankin Scale score of 4 to 6), as compared with

192 hemia-related infarction and poor outcome (a modified Rankin Scale score of 4, 5, or death at 3 mo).

193 Median (interquartile range) modified Rankin Scale score was 2 (1-3) at discharge and

194 The modified Rankin Scale score was analyzed by ordinal logi

195 The modified Rankin Scale score was used to assess clinical

196 no history of stroke and prestroke handicap (modified Rankin Scale score, < 2).

197 al : 6.7%, 19.7%), a favorable outcome ( mRS modified Rankin Scale score, </=2) was seen in 42.5% of

198 The rate of functional independence (modified Rankin scale score, 0 to 2) was higher in the i

199 o treat, 43) and better functional outcomes (modified Rankin Scale score, 0-1) at discharge (24.1% vs

200 Scale score, 0-2), 90-day excellent outcome (modified Rankin Scale score, 0-1), and occurrence of any

201 outcomes included 90-day favorable outcome (modified Rankin Scale score, 0-2), 90-day excellent outc

202 Factors associated with favorable (modified Rankin Scale score, 0-3) vs unfavorable functio

203 on the occurrence of an unfavorable outcome (modified Rankin Scale score, 3-6) (odds ratio, 1.20; 95%

204 tors associated with an unfavorable outcome (modified Rankin Scale score, 3-6), any new intraventricu

205 43) of survivors had an unfavorable outcome (modified Rankin Scale score, 3-6).

206 associated with death or severe disability (modified Rankin Scale score, 4-6) at 3 months in a multi

207 Part II score, the UPDRS Part III score, the modified Rankin Scale score, level of education, and tre

208 in response to external stimuli) and 6-month modified Rankin scale score.

209 edema expansion rate at 24 hours and 90-day modified Rankin Scale score.

210 uded neurological outcome assessed using the modified Rankin Scale (score 0 [no symptoms] through 6 [

211 vorable outcome (modified Rankin Scale [ mRS modified Rankin Scale ] score, </=2), and rates of SICH

212 Functional outcomes were recorded with modified Rankin Scale (scored from 0 [no symptoms] to 6

213 since first antibody detection), the median modified Rankin scale scores (excluding the four deaths)

214 ithrombotic use and (1) death or dependency (modified Rankin scale scores 3-6) were analysed using lo

215 The distribution of modified Rankin scale scores at 1 year, 5 years, or fina

216 ologic deficit at 14 days but higher (worse) modified Rankin Scale scores at 3 months (median [interq

217 he secondary outcome was an ordinal shift in modified Rankin Scale scores at 90 days, assessed by inv

218 f death and major disability were defined by modified Rankin Scale scores at 90 days.

219 tus showed that the distributions of 3-month modified Rankin Scale scores differed across white matte

220 Good outcomes, as defined by 90-day modified Rankin Scale scores of 0 to 2, were analyzed by

221 Modified Rankin scale scores were assigned based on tele

222 ries reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody

223 t quintile was associated with worse 3-month modified Rankin Scale scores: adjusted odds ratio for th

224 independently associated with worse 3-month modified Rankin Scale scores; adjusted odds ratios (95%

225 versus the first quintile) had worse 3-month modified Rankin Scale scores; adjusted odds ratios were

226 al status was defined by 5 outcome measures: Modified Rankin Scale, Symbol Digit Modalities Test, PDQ

227 tervention would lead to lower scores on the modified Rankin scale than would control care (shift ana

228 In the analysis using the modified Rankin scale, the comparable rate was 52% in bo

229 In ordinal analysis of the modified Rankin Scale, the median (IQR) value was 1 (1-6

230 the primary analysis of scores on the 90-day modified Rankin scale, there was no interaction between

231 score for disability on the utility-weighted modified Rankin scale (which ranges from 0 [death] to 10

232 ability (defined by a score of 0 to 4 on the modified Rankin scale, which ranges from 0 [no symptoms]

233 l independence (a score of 0, 1, or 2 on the modified Rankin scale, which ranges from 0 to 6, with hi

234 ctory function (i.e., a score of </=3 on the modified Rankin scale, which ranges from 0 to 6, with hi

235 lity at 90 days, as assessed by means of the modified Rankin scale (with scores ranging from 0 [no sy

236 dependence (defined as a score of 0-2 on the modified Rankin Scale, with 0 indicating no disability a